Episode 25: What to Know about Grade 3 Poorly Differentiated Neuroendocrine Carcinoma (NEC)

What are Grade 3 Poorly Differentiated Neuroendocrine Carcinoma (NEC)? What makes NEC unique? Can a NET transform to NEC? Dr Nitja Raj from Memorial Sloan Kettering Cancer Center in New York City explains NEC tumor biology and how it guides treatment strategy. She also discusses current clinical trials and research. For more information, visit LACNETS.org/podcast/24. For more information, visit NCF.net.